Cargando…
Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases.
ER content of primary tumour tissue has been examined in 704 patients presenting with operable breast cancer. The median follow-up is now 84 months and no patient has received adjuvant therapy of any kind. ER status is related to histological grade, menopausal status, initial site of metastases and...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1987
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001565/ https://www.ncbi.nlm.nih.gov/pubmed/3814477 |
_version_ | 1782135631120433152 |
---|---|
author | Williams, M. R. Todd, J. H. Ellis, I. O. Dowle, C. S. Haybittle, J. L. Elston, C. W. Nicholson, R. I. Griffiths, K. Blamey, R. W. |
author_facet | Williams, M. R. Todd, J. H. Ellis, I. O. Dowle, C. S. Haybittle, J. L. Elston, C. W. Nicholson, R. I. Griffiths, K. Blamey, R. W. |
author_sort | Williams, M. R. |
collection | PubMed |
description | ER content of primary tumour tissue has been examined in 704 patients presenting with operable breast cancer. The median follow-up is now 84 months and no patient has received adjuvant therapy of any kind. ER status is related to histological grade, menopausal status, initial site of metastases and subsequent response to endocrine therapy. A significant advantage in terms of survival is found in ER positive patients which is confined to those lymph node positive at mastectomy. DFI is also significantly related to ER status in lymph node positive patients. Survival after the symptomatic presentation of metastases and the institution of endocrine therapy is prolonged in patients with ER positive tumours. The overall response rate to endocrine therapy in assessable patients with ER positive tumours is 32%. By combining the ER status and histological grade of tumour tissue, a group of patients comprising 28% of those assessable to endocrine therapy can be identified (ER positive, grade I and II) with a response rate of 46%. |
format | Text |
id | pubmed-2001565 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1987 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20015652009-09-10 Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Williams, M. R. Todd, J. H. Ellis, I. O. Dowle, C. S. Haybittle, J. L. Elston, C. W. Nicholson, R. I. Griffiths, K. Blamey, R. W. Br J Cancer Research Article ER content of primary tumour tissue has been examined in 704 patients presenting with operable breast cancer. The median follow-up is now 84 months and no patient has received adjuvant therapy of any kind. ER status is related to histological grade, menopausal status, initial site of metastases and subsequent response to endocrine therapy. A significant advantage in terms of survival is found in ER positive patients which is confined to those lymph node positive at mastectomy. DFI is also significantly related to ER status in lymph node positive patients. Survival after the symptomatic presentation of metastases and the institution of endocrine therapy is prolonged in patients with ER positive tumours. The overall response rate to endocrine therapy in assessable patients with ER positive tumours is 32%. By combining the ER status and histological grade of tumour tissue, a group of patients comprising 28% of those assessable to endocrine therapy can be identified (ER positive, grade I and II) with a response rate of 46%. Nature Publishing Group 1987-01 /pmc/articles/PMC2001565/ /pubmed/3814477 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Williams, M. R. Todd, J. H. Ellis, I. O. Dowle, C. S. Haybittle, J. L. Elston, C. W. Nicholson, R. I. Griffiths, K. Blamey, R. W. Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. |
title | Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. |
title_full | Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. |
title_fullStr | Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. |
title_full_unstemmed | Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. |
title_short | Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. |
title_sort | oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001565/ https://www.ncbi.nlm.nih.gov/pubmed/3814477 |
work_keys_str_mv | AT williamsmr oestrogenreceptorsinprimaryandadvancedbreastcanceraneightyearreviewof704cases AT toddjh oestrogenreceptorsinprimaryandadvancedbreastcanceraneightyearreviewof704cases AT ellisio oestrogenreceptorsinprimaryandadvancedbreastcanceraneightyearreviewof704cases AT dowlecs oestrogenreceptorsinprimaryandadvancedbreastcanceraneightyearreviewof704cases AT haybittlejl oestrogenreceptorsinprimaryandadvancedbreastcanceraneightyearreviewof704cases AT elstoncw oestrogenreceptorsinprimaryandadvancedbreastcanceraneightyearreviewof704cases AT nicholsonri oestrogenreceptorsinprimaryandadvancedbreastcanceraneightyearreviewof704cases AT griffithsk oestrogenreceptorsinprimaryandadvancedbreastcanceraneightyearreviewof704cases AT blameyrw oestrogenreceptorsinprimaryandadvancedbreastcanceraneightyearreviewof704cases |